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Abstract. – OBJECTIVE: Polymyalgia
rheumatica (PMR) is an inflammatory disease
that affects people aged > 50 years, and is char-
acterised by pain and morning stiffness in the
shoulder and pelvic girdle with synovitis of the
proximal joints and extra-articular synovial
structures. It is currently mainly treated with glu-
cocorticoids (GCs). The aim of the study was to
evaluate changes in inflammatory markers and
their correlations with cortisol levels after treat-
ment with 6-methylprednisolone (6-MP) or modi-
fied-release prednisone (MR-P) in patients with
“early” PMR.
PATIENTS AND METHODS: The study in-
volved 81 GC-naïve with “early” PMR diagnosed
on the basis of the 2012 EULAR/ACR criteria: 38
treated with 6-MP at a starting dose of 12 mg at
8.00 a.m, gradually tapered to 8, 4 and 2 mg/day,
and 43 treated with MR-P at a starting dose of 10
mg at 10 p.m, tapered to 7, 5, 3, 2 and 1 mg. The
markers of inflammation (ESR mm/h, CRP mg/dL
and fibrinogen mg/dL), the circulating serum lev-
els of cytokines (TNFα and IL-6), and morning
serum cortisol levels were evaluated at baseline
and during GC treatment. 
RESULTS: There were significant differences
between baseline and the end of treatment in the
serum levels of IL-6 (5.3 ± 9.3 vs 2.8 ± 3.3 pg/mL;
p < 0.05) and CRP (2.1 ± 3.3 vs 0.9 ± 1.7 mg/dL; p
< 0.01) in the patients treated with MR-P, and in
serum cortisol levels (15.8±6.4 vs 13.6+5.6
µg/dL; p < 0.01) in the patients treated with 6-MP.
After the first month of treatment, 76.7% of the
patients treated with MR-P had IL6 levels at or
below the upper normal limit, whereas 52.6% of
those treated with 6-MP had normal IL6 levels (p
< 0.05). There was also a significant difference in
the percentage of patients in whom the daily GC
dose was tapered within eight months (6.7% in
the MR-P group vs 25% in the 6-MP group; p <
0.001) and, by the end of the study, respectively
59.5% vs 35.1% patients were receiving a low GC
dose or had discontinued treatment altogether
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(OR 2.7, 95% CI 1.0-6.77; p < 0.001). After six and
12 months, respectively 10.3% and 14.3% of the
patients had discontinued MR-P, as against none
of the patients treated with 6-MP (p < 0.05).
CONCLUSIONS: In this prospective observa-
tional study of PMR patients receiving low-dose
GCs, the changes in inflammatory markers were
similar in those treated with 6-MP or MR-P,
whereas morning cortisol levels remained un-
changed only in the MR-P group. During the first
month of treatment, MR-P chronotherapy given
at bedtime significantly decreased IL-6 levels.
The percentage of patients stopping GC treat-
ment was higher in the MR-P group than in the 6-
MP group.
Key Words:
Polymyalgia rheumatica, Modified-release pred-
nisone, 6-methylprednisolone.
Introduction
Polymyalgia rheumatica (PMR) is an inflam-
matory disease that affects people aged > 50 years.
It may be ‘isolated’ or associated with giant cell
arteritis (GCA), and is characterized by pain and
morning stiffness in the shoulder and pelvic girdle
with synovitis of the proximal joints and extra-ar-
ticular synovial structures. The first case was de-
scribed in 18881, but the term “polymyalgia
rheumatica” was proposed by Barber in 19572. 
PMR is currently mainly treated with gluco-
corticoids (GCs), which is the gold standard
treatment as it reduces symptoms and suppresses
inflammation within a few weeks. GCs such as
prednisone inhibit the circadian release of pro-in-
flammatory cytokines such as IL6, and hence re-
duce the duration of morning stiffness, and a
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short course of treatment at a dose of > 10
mg/day is associated with fewer relapses than
lower doses3. However, immediate-release pred-
nisone is taken upon waking, which is too late to
have an impact on morning symptoms and the in-
flammatory effects of IL-64,5, and the more ap-
propriate timing of drug administration or the use
of modified-release prednisone (MR-P) prepara-
tions may lead to an improvement in the duration
of morning stiffness.
The circadian administration of prednisone in
patients with rheumatoid arthritis (RA) as in the
CAPRA-1 and -2 studies showed that the opti-
mised administration of low-dose MR-P (de-
signed to be released at 3.00 a.m. in order to con-
trol increasing IL-6 levels) improves the
risk/benefit ratio of long-term GC treatment4,5.
An MR-P formulation developed on the basis of
biological rhythms (chronotherapy) delivers
prednisone at the most physiologically efficient
time in order to relieve the morning symptoms of
RA, and has no adverse impact on the hypothala-
mic-pituitary-adrenal axis. 
The aim of this study was to evaluate the
changes in inflammation markers and their corre-
lations with cortisol levels after treatment with 6-
methylprednisolone (6-MP) or MR-P in patients
with “early” PMR.
Patients and Methods
The study involved 81 GC-naïve with “early”
PMR diagnosed on the basis of the 2012 EU-
LAR/ACR criteria: 38 treated with 6-MP at a
starting dose of 12 mg at 8.00 a.m, gradually ta-
pered to 8, 4 and 2 mg/day, and 43 treated with
MR-P at a starting dose of 10 mg at 10 p.m, ta-
pered to 7, 5, 3, 2 and 1 mg. Blood was drawn
between 8.00 a.m and 9.00 a.m. when the pa-
tients visited the outpatient clinic at baseline, and
every month during GC treatment. The blood
was immediately centrifuged and the serum was
stored at –80°C. Written informed consent was
obtained from all patients and the study was ap-
proved by the Ethics Committee of San Giovanni
Di Dio Hospital, Florence, Italy.
The evaluated inflammation markers were the
erythrocyte sedimentation rate (ESR, mm/h), and
the levels of C-reactive protein (CRP, mg/dL) and
fibrinogen (mg/dL). Circulating interleukin-6 lev-
els (IL-6, upper normal limit [UNL] < 3.0 pg/mL)
were determined by means of a human IL6 instant
enzyme-linked immunosorbent assay (ELISA)
(eBioscience, Bender MedSystem GmbH, Vienna,
Austria), and circulating tumour necrosis factor-al-
pha levels (TNFα, UNL < 15.6 pg/mL) by means
of a quantitative sandwich enzyme immunoassay
technique (Human TNF-alpha Quantikine Im-
munoassay, RD System Inc., Minneapolis, MN,
USA). Morning serum cortisol levels (µg/dL) were
assessed at baseline and every month during GC
treatment by means of an electrochemiluminis-
cence immunoassay (ECLIA, Roche, Mannheim,
Germany). 
Statistical Analysis
The continuous variables are expressed as
mean values and standard deviation, and were
compared within and between the groups using
the non parametric Mann-Whitney U test (paired
and two- sample independent tests) at the differ-
ent times of follow-up. The categorical variables
are expressed as frequencies and percentages,
and were compared using the Cochrane Q test.
Odds ratios (OR) were calculated to compare the
groups on different daily doses at the end of the
follow-up.
Results
Table I shows the patients’ demographic char-
acteristics and baseline laboratory parameters:
there were significant differences between the
MR-P and 6-MP groups in the levels of cortisol
(11.5 ± 6.7 vs 15.8±6.4 µg/mL; p < 0.01) and IL-
6 (5.3 ± 9.3 vs 1.9±1.3 pg/mL; p < 0.05). 
Table II shows the changes in inflammation
markers, cytokine and cortisol levels between base-
line and the last visit. There were significant
changes in the levels of IL-6 (5.3±9.3 vs 2.8±3.3
pg/mL, p < 0.05) and CRP (2.1±3.3 vs 0.9±1.7
mg/dL; p < 0.01) in the patients treated with MR-P,
and in serum cortisol levels (15.8±6.4 vs 13.6+5.6
µg/dL; p < 0.01) in the patients treated with 6-MP.
Figure 1 shows IL-6 levels in both groups: after the
first month of GC treatment; 76.7% of the MR-P
patients had IL-6 levels ≤ UNL, whereas 52.6% of
those treated with 6-MP had normal IL6 levels (p <
0.05) (Figure 2). The tapering of the daily GC dose
was significantly different between the two groups
(p < 0.001; Figure 3). There was also a significant
difference in the percentage of daily of GC dose ta-
pered within eight months (6.7% in the MR-P
group vs 25% in the 6-MP group; p < 0.001) (Fig-
ure 4) and, by the end of the study, respectively
59.5% vs 35.1% patients were receiving a low GC
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MR-P 6-MP p value
No. of patients 43 38 ns
Age, years 73.9 ± 8.5 74.0 ± 8.2 ns
No. of males (%) 20 (47%) 14 (37%) ns
No. of females (%) 23 (53%) 24 (63%) ns
ESR, mm/h 33.6 ± 20.9 31.2 ± 17.3 ns
CRP, mg/dL 2.1 ± 3.3 1.5 ± 1.7 ns
Fibrinogen mg/dL 464 ± 143 487 ± 168 ns
Serum cortisol, µg/dL 11.5 ± 0.7 15.8 ± 6.4 < 0.01
Serum TNFα, pg/mL (× UNL) 1.12 ± 6.7 1.1 ± 0.3 ns
Serum IL6, pg/mL (No. of with patients > UNL) 16 21 ns
Serum IL6, pg/mL (× UNL) 5.3 ± 9.3 1.9 ± 1.3 < 0.05
Table I. Demographic characteristics and laboratory parameters at baseline.
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; TNF: tumour necrosis factor-alpha; IL-6: interleukin-6; UNL:
upper normal limit.
MR-P MR-P 6-MP 6-MP
Baseline Last visit Baseline Last visit
ESR, mm/h 33.6 ± 20.9 27.5 ± 20.6 31.2 ± 17.3 25.5 ± 19.0
CRP, mg/dL 2.1 ± 3.3 0.9 ± 1.7°° 1.5 ± 1.7 1.1± 1.1
Fibrinogen, mg/dL 464 ± 143 426 ± 112 487 ± 168 455 ± 93
Serum cortisol, µg/dL 11.5 ± 6.7 12.0 ± 4.1 15.8 ± 6.4** 13.6 ± 5.6
Serum TNFα, pg/mL (× UNL) 1.1 ± 0.6 2.3 ± 8.2 1.1 ± 0.3 2.5 ± 6.3
Serum IL6, pg/mL (× UNL 5.3 ± 9.3 2.8 ± 3.3* 1.9 ± 1.3* 2.0 ± 2.9
Daily dose, mg 10 3.0 ± 1.9 12 3.4 ± 1.2
% of starting dose 29 ± 20 28 ± 11
Follow-up, days 179 ± 70 150 ± 58
Table II. Inflammation markers, cytokine levels and glucocorticosteroid dose.
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; TNF: tumour necrosis factor; IL-6: interleukin-6; UNL: upper
normal limit. **p < 0.1 vs baseline MR-P; *p < 0.05 vs baseline MR-P; °°p < 0.01 vs baseline.
Figure 1. IL-6 levels from baseline to month four.
748
dose or had discontinued treatment altogether (OR
2.7, 95% CI 1.0-6.77; p < 0.001) (Figure 5). After
six and 12 months, respectively 10.3% and 14.3%
of the patients had discontinued MR-P, as against
none of the patients treated with 6-MP (p < 0.05)
(Figure 6).
Discussion
In this non-randomized, prospective observa-
tional study of PMR patients receiving low-dose
GCs, the changes in inflammatory markers were
similar in those treated with 6-MP or MR-P,
whereas morning cortisol levels remained un-
changed only in the MR-P group. An MR-P in-
duced improvement in morning stiffness was
observed after 9-12 months during the open-la-
bel extension of the CAPRA-1 study4, and this
finding is in line with those of observational
studies of adult RA patients. The evening ad-
ministration of MR-P for up to 12 months is tol-
erated as well as the evening administration of
placebo or morning immediate-release pred-
nisone, and longer-term treatment with the
evening administration of MR-P improves
morning stiffness in RA patients7. In the 9-
month extension phase of CAPRA-1, the dura-
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Figure 2. Percentage of patients with IL-6 levels ≤ UNL.
Figure 3. Tapering of daily of GC dose (absolute values).
tion of morning stiffness was reduced by 55%
from the baseline of the double-blind phase in
all of the patients after the first three months of
treatment (i.e. after a total of six months of
prednisone treatment), regardless of the pred-
nisone formulation received, and prolonged
MR-P treatment led to 45-61% reduction after
six and nine months (i.e. after a total of nine
and 12 months of prednisone treatment)7. 
In our study of low-dose GCs, one month of
MR-P chronotherapy given at bedtime induced a
greater decrease in IL-6 levels. RA patients expe-
rience a circadian increase in endogenous cortisol
levels during the evening8, but this is not sufficient
to counter the increase in IL-6 levels9. However,
two randomized trials of 12 weeks’ treatment with
evening MR-P in RA patients (3-10 mg4 or an
equivalent of 5 mg5) found a significant reduction
in IL-6 levels (a marker of inflammatory disease
activity)10 in comparison with placebo5 or the
morning administration of immediate-release
prednisone4. In the placebo-controlled trial, the
geometric mean IL-6 titre ratio was 0.8 (95% CI
0.7-0.9) in favour of MR-P (baseline 5 pg/mL)5; in
the trial comparing MR-P with immediate-release
prednisone, MR-P led to a 28.6% reduction in IL-
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Figure 4. Tapering of GC dose (reduction from starting dose).
Figure 5. Daily GC dose at last follow-up.
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6 levels whereas there was no change in the com-
parator group (p = 0.0322)4. After a further nine
months of open-label MR-P therapy7, IL-6 levels
significantly decreased by 50% in comparison
with the baseline level of the double-blind phase
(p < 0.05). Furthermore, another study of RA pa-
tients has shown that evening MR-P 5 mg once
daily for two weeks affected the circadian varia-
tion in IL-6 levels, with peak levels reduced by
50% and a change in the time of peak levels from
8:05 a.m. to 1:21 a.m.11.
The role of IL-6 has been investigated in vari-
ous studies: one found an association between
the IL-6 -174 allele C and PMR manifestations in
patients with GCA12, whereas an Italian study
found the IL-6 promoter polymorphism at posi-
tion -174 in both PMR patients and controls13.
These findings suggest that many genes are in-
volved in susceptibility to, and the severity of
PMR, and that associations with polymorphisms
may be different in different populations. The IL-
6 receptor antagonist, monoclonal antibody
tocilizumab (TCZ), has been used to treat PMR
and correlated with the levels of circulating IL-6
in patients with active disease14. Four papers15-18
have described its use in a total of nine PMR pa-
tients (one with newly diagnosed PMR, one with
relapsed PMR, and seven who developed PMR
during the tapering of GCs prescribed for GCA),
three of whom (one with PMR and two with
PMR/GCA) were GC-naïve: eight received a
dose of 8 mg/kg/month and one a dose of 4
mg/kg/month, and all experienced clinical and
serological remission.
GCs represent the gold standard for PMR
treatment. Initial daily prednisone doses of > 10
mg are associated with fewer relapses and shorter
GC therapy than lower doses, but starting at dos-
es of > 15 mg/day have been related to greater
GC accumulation and frequent GC-related ad-
verse events19. There is no universally accepted
regimen, but the British Society for Rheumatol-
ogy (BSR) suggests that prednisolone (or its
equivalent) should be used at 15 mg/day for three
weeks, at 12.5 mg for a further three weeks, and
then at 10 mg for 4-6 weeks before being tapered
by 1 mg every 4-8 weeks provided no flares oc-
cur20. Many patients discontinue GCs between
six months and two years after the onset of clini-
cal symptoms, but others may require long-stand-
ing therapy. In our study, tapering was more
rapid with MR-P than with 6-MP, and more MR-
P patients could discontinue GC treatment alto-
gether.
Conclusions 
In this non-randomized, prospective observa-
tional study of low-dose GC treatment, the
changes in inflammatory markers were similar in
PMR patients treated with 6-MP or MR-P,
whereas morning cortisol levels remained un-
changed only in the MR-P group. During the first
month of treatment, MR-P chronotherapy given
at bedtime significantly decreased IL-6 levels,
and the percentage of patients stopping GC treat-
ment was higher in the MR-P group than in the
6-MP group.
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Figure 6. Percentage of the patients discontinning GC.
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